Skip to main content

Advertisement

SpringerLink
Log in

Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic Cholangiocarcinoma

  • Hepatobiliary Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Intrahepatic cholangiocarcinoma (ICC) is rare but is increasing in incidence. While hepatectomy can be curative, the benefit of adjuvant therapy (AT) remains unclear. We utilized the National Cancer Data Base (NCDB) to isolate predictors of overall survival, describe the national pattern of AT administration, and identify characteristics of patients who experience a survival benefit from AT following resection for ICC.

Methods

Patients who were diagnosed with ICC between 1998 and 2006 and underwent surgical resection were identified through the NCDB. Kaplan–Meier and Cox regression analyses evaluated differences in overall survival between patients who received AT and those who did not.

Results

Overall, 638 patients who underwent surgery for ICC were identified. Multivariate Cox regression analysis identified positive lymph nodes, unexamined lymph nodes, positive margins, and lack of AT as predictors of decreased overall survival; 28.1 % of patients had positive margins while 20.1 % had positive nodes. These patients, as well as those who were younger and had fewer co-morbid conditions, were most likely to receive AT. After adjusting for other prognostic variables, patients were found to significantly benefit from AT if they had positive lymph nodes [chemotherapy: hazard ratio (HR) 0.54, p = 0.0365; chemoradiation: HR 0.50, p = 0.005] or positive margins (chemotherapy: HR 0.44, p = 0.0016; chemoradiation: HR 0.57, p = 0.0039).

Conclusions

Positive lymph nodes and positive margins were associated with poor survival after resection for ICC. After controlling for other prognostic factors, AT was associated with significant survival benefits among patients with positive nodes or positive margins.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 2008;10(2):77-82.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1198-203.

    Article  PubMed  Google Scholar 

  3. Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84-96.

    Article  PubMed  Google Scholar 

  4. Yedibela S, Demir R, Zhang W, Meyer T, Hohenberger W, Schönleben F. Surgical treatment of mass-forming intrahepatic cholangiocarcinoma: an 11-year Western single-center experience in 107 patients. Ann Surg Oncol. 2009;16(2):404-12.

    Article  PubMed  Google Scholar 

  5. Uchiyama K, Yamamoto M, Yamaue H, et al. Impact of nodal involvement on surgical outcomes of intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2011;18(3):443-52.

    Article  PubMed  Google Scholar 

  6. Murakami Y, Uemura K, Sudo T, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol. 2011;18(3):651-8.

    Article  PubMed  Google Scholar 

  7. Bhudhisawasdi V, Talabnin C, Pugkhem A, et al. Evaluation of postoperative adjuvant chemotherapy for intrahepatic cholangiocarcinoma patients undergoing R1 and R2 resections. Asian Pac J Cancer Prev. 2012;13 Suppl:169-74.

    PubMed  Google Scholar 

  8. Murakami S, Ajiki T, Okazaki T, et al. Factors affecting survival after resection of intrahepatic cholangiocarcinoma. Surg Today. 2014;44(10):1847–54.

    Article  PubMed  Google Scholar 

  9. Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M, Gruenberger T. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008;15(10):2787-94.

    Article  PubMed  Google Scholar 

  10. Ercolani G, Vetrone G, Grazi GL, et al. Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg. 2010;252(1):107-14.

    Article  PubMed  Google Scholar 

  11. Fisher SB, Patel SH, Kooby DA, et al. Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis. HPB (Oxford). 2012;14(8):514-22.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Konstadoulakis MM, Roayaie S, Gomatos IP, Labow D, Fiel MI, Miller CM, et al. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery. 2008;143(3):366-74.

    Article  PubMed  Google Scholar 

  13. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149(6):565–574.

    Article  Google Scholar 

  14. Lang H, Sotiropoulos GC, Frühauf NR, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg. 2005;241(1):134-43.

    PubMed Central  PubMed  Google Scholar 

  15. Hemming AW, Reed AI, Langham MR Jr, Fujita S, Howard RJ. Combined resection of the liver and inferior vena cava for hepatic malignancy. Ann Surg. 2004;239(5):712-9.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Sulpice L, Rayar M, Boucher E, Pracht M, Meunier B, Boudjema K. Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg. 2012;99(12):1711-7.

    Article  CAS  PubMed  Google Scholar 

  17. Farges O, Fuks D, Boleslawski E, et al. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 Study Group. Ann Surg. 2011;254(5):824-29.

    Article  PubMed  Google Scholar 

  18. Zhu AX, Knox JJ. Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues. Oncologist. 2012;17(12):1504-7.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25(2):391-8.

    Article  CAS  PubMed  Google Scholar 

  20. Liu RQ, Shen SJ, Hu XF, Liu J, Chen LJ, Li XY. Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors. Cancer Cell Int. 2013;13(1):99.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Dodson RM, Weiss MJ, Cosgrove D, et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg. 2013;217(4):736-750.

    Article  PubMed  Google Scholar 

  22. Poultsides GA1, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am. 2010;90(4):817–37.

  23. Commission on Cancer. FORDS Facility Oncology Registry Data Standards: Revised for 2013. Chicago: American College of Surgeons Commission on Cancer; 2013.

    Google Scholar 

  24. Hyder O, Marques H, Pulitano C, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg. 2014;149(5):432–8.

    Article  PubMed  Google Scholar 

  25. Marubashi S, Gotoh K, Takahashi H, Ohigashi H, Yano M, Ishikawa O, et al. Prediction of the postoperative prognosis of intrahepatic cholangiocarcinoma (ICC): importance of preoperatively-determined anatomic invasion level and number of tumors. Dig Dis Sci. 2014;59(1):201-13.

    Article  PubMed  Google Scholar 

  26. Clark CJ, Wood-Wentz CM, Reid-Lombardo KM, Kendrick ML, Huebner M, Que FG. Lymphadenectomy in the staging and treatment of intrahepatic cholangiocarcinoma: a population-based study using the National Cancer Institute SEER database. HPB (Oxford). 2011;13(9):612-20.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Choi SB, Kim KS, Choi JY, Park SW, Choi JS, Lee WJ, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol. 2009;16(11):3048-56.

    Article  PubMed  Google Scholar 

  28. Maithel SK, Gamblin TC, Kamel I, Corona-Villalobos CP, Thomas M, Pawlik TM. Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer. 2013;119(22):3929-42.

    Article  PubMed  Google Scholar 

  29. Roayaie S, Guarrera JV, Ye MQ, et al. Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. J Am Coll Surg. 1998;187(4):365-72.

    Article  CAS  PubMed  Google Scholar 

  30. National Comprehensive Cancer Network®. Hepatobiliary cancers (version 2.2014). Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines_nojava.asp#site. Accessed 24 Aug 2014.

  31. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934-40.

    Article  PubMed  Google Scholar 

  32. Chen YX, Zeng ZC, Tang ZY, et al. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer. 2010;10:492.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Hoffmann RT, Paprottka PM, Schön A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35(1):105-16.

    Article  PubMed  Google Scholar 

  34. Shinohara ET, Mitra N, Guo M, Metz JM. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2008;72(5):1495-501.

    Article  PubMed  Google Scholar 

  35. Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16(1):14-22.

    Article  PubMed  Google Scholar 

  36. In H, Bilimoria KY, Stewart AK, Wroblewski KE, Posner MC, Talamonti MS, et al. Cancer recurrence: an important but missing variable in national cancer registries. Ann Surg Oncol. 2014;21(5):1520–9.

    Article  PubMed  Google Scholar 

  37. Gu FM, Gao Q, Shi GM, et al. Intratumoral IL-17+ cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2012;19(8):2506-14.

    Article  PubMed  Google Scholar 

  38. Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144(4):829-40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Disclosures

Malini D. Sur, Haejin In, Susan M. Sharpe, Marshall S. Baker, Ralph R. Weichselbaum, Mark S. Talamonti, and Mitchell C. Posner have no commercial interests in the subject of the study.

Author information

Authors and Affiliations

  1. Department of Surgery, The University of Chicago, Chicago, IL, USA

    Malini D. Sur MD, Haejin In MD, MBA, MPH, Susan M. Sharpe MD & Mitchell C. Posner MD

  2. Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA

    Marshall S. Baker MD & Mark S. Talamonti MD

  3. Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL, USA

    Ralph R. Weichselbaum MD

Authors
  1. Malini D. Sur MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haejin In MD, MBA, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan M. Sharpe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marshall S. Baker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ralph R. Weichselbaum MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mark S. Talamonti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mitchell C. Posner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Malini D. Sur MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sur, M.D., In, H., Sharpe, S.M. et al. Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol 22, 2209–2217 (2015). https://doi.org/10.1245/s10434-014-4275-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-4275-4

Keywords

Search

Navigation